Primary care trust backs down on decision not to fund eye medication
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Public and political pressure yesterday forced an NHS trust to review its decision not to fund the purchase of a sight-saving drug for a former Labour MP.
Kirklees and Calderdale primary care trust responded to a challenge by Alice Mahon in this paper, highlighting NHS inequalities that deny treatment to thousands facing blindness, including herself.
Mrs Mahon, 69, who was MP for Halifax for 18 years, has already lost most of the sight in one eye because of "wet" age-related macular degeneration (AMD). Thousands of other people are affected by the condition.
Last November her PCT refused a request by her consultant at Calderdale Royal Hospital, near Halifax, to buy the new drug Lucentis, which has been shown in trials to improve vision in a third of patients with wet AMD and to halt deterioration in most of the rest. Yesterday the PCT said news that the drug had received its European licence meant it would reconsider.
Mrs Mahon said: "If this review means that people are going to get the treatment and get it quickly then it's extremely welcome news."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments